Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Name: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Published: 2023
License: Public Domain

Pfizer · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

magnetism multiple-myeloma

multiple myeloma, elranatamab, post trial access, roll-over study, extension study, mm-15, magnetismm15, bcma, bcma antibody, magnetism, bispecific antibody, elrexfio

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 905100
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.